The MSRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis.
Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics),
credit:
devices, clinical guidance, interventions, health behavioral modifications and/or emerging approaches and technologies.
Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through larger-scale Phase I and II trials to determine efficacy in relevant patient populations.